Thomas, Sharyn
Mohammed, Fiyaz
Reijmers, Rogier M. http://orcid.org/0000-0001-7471-7715
Woolston, Annemarie http://orcid.org/0000-0002-8932-2895
Stauss, Theresa
Kennedy, Alan http://orcid.org/0000-0003-0384-3866
Stirling, David http://orcid.org/0000-0001-6802-4103
Holler, Angelika
Green, Louisa http://orcid.org/0000-0002-7780-3536
Jones, David http://orcid.org/0000-0001-8626-3765
Matthews, Katherine K.
Price, David A. http://orcid.org/0000-0001-9416-2737
Chain, Benjamin M. http://orcid.org/0000-0002-7417-3970
Heemskerk, Mirjam H. M. http://orcid.org/0000-0001-6320-9133
Morris, Emma C. http://orcid.org/0000-0003-4834-1130
Willcox, Benjamin E. http://orcid.org/0000-0002-6113-2109
Stauss, Hans J. http://orcid.org/0000-0003-4340-7911
Article History
Received: 23 November 2018
Accepted: 26 August 2019
First Online: 1 October 2019
Competing interests
: H.J.S. is share holder of Cell Medica and obtained research funding from Cell Medica and Apollo Ltd. H.J.S. and E.M. are founders, consultants, and share holders of Quell Therapeutics. S.T., F.M., B.E.W., and H.J.S. are inventors of a patent of the dominant TCR technology. The remaining authors declare no competing interests.